Search Within

Center for Hematologic Malignancies

  1. "General Medicine Services"
Formats
  1. Meeting Abstract (50)
  2. Journal Article (25)
  3. Review (4)
  4. Conference Paper (2)
  5. Book Section (1)
Groups
  1. General Medicine Services (82)
  2. Department of Medicine (74)
  3. Hematologic Malignancies, Division of (65)
  4. Survivorship Research (58)
  5. Hematologic Malignancies Research (47)
  6. Epidemiology and Biostatistics (46)

More Groups

People
  1. Dhwani Patel (34)
  2. Alexander Lesokhin (33)
  3. Carlyn Rose Tan (33)
  4. Hani Hassoun (33)
  5. Malin Hultcrantz (33)
  6. Neha Korde (33)

More People

Years
  1. 2023 (14)
  2. 2022 (12)
  3. 2021 (6)
  4. 2020 (11)
  5. 2019 (4)
  6. 2018 (5)

More Years

Publications
  1. Blood (29)
  2. Journal of Clinical Oncology (12)
  3. Clinical Lymphoma, Myeloma and Leukemia (9)
  4. Cancer (2)
  5. Journal of Pediatric Surgery (2)
  6. Annals of Surgery (1)

More Publications

Publishers
  1. American Society of Hematology (29)
  2. American Society of Clinical Oncology (12)
  3. Elsevier Inc. (11)
  4. American Association for Cancer Research (3)
  5. Nature Publishing Group (3)
  6. Springer (3)

More Publishers

Results (82)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) and daratumumab, carfilzomib, lenalidomide and dexamethasone (DKRd) as induction therapy in newly diagnosed multiple myeloma
    Meeting Abstract

    Tan, C.; Maclachlan, K. H.; Nemirovsky, D.; Derkach, A.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U. A.; Rajeeve, S.; Patel, D.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Identifying causes of unscheduled healthcare interactions and changes to patient disposition in individuals receiving outpatient commercial bispecific antibody therapy in relapsed/refractory multiple myeloma (RRMM)
    Meeting Abstract

    Howard, A. J.; Shekarkhand, T.; Hamadeh, I. S.; Wang, A.; Patel, D.; Tan, C.; Hultcrantz, M.; Mailankody, S.; Hassoun, H.; Shah, U. A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Carfilzomib,lenalidomide and dexamethasone (KRd) as induction therapy in high-risk newly diagnosed multiple myeloma
    Meeting Abstract

    Tan, C.; Korde, N.; Derkach, A.; Hultcrantz, M.; Maclachlan, K. H.; Hassoun, H.; Mailankody, S.; Shah, U. A.; Rajeeve, S.; Patel, D.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Patterns of cytokine release syndrome with teclistamab in relapsed/refractory multiple myeloma with or without prior T-cell redirection therapy
    Meeting Abstract

    Hamadeh, I. S.; Shekarkhand, T.; Rueda, C.; Firestone, R.; Wang, A.; Korde, N.; Hultcrantz, M.; Lesokhin, A.; Mailankody, S.; Hassoun, H.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Evaluating the effect of evolving changes in serum biomarkers on the risk of progression in smoldering multiple myeloma
    Meeting Abstract

    Akhlaghi, T.; Nemirovsky, D.; Maclachlan, K. H.; Korde, N.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Patel, D.; Shah, U. A.; Tan, C.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Clinical outcomes associated with del(17p) in newly diagnosed multiple myeloma treated with triplet and daratumumab-based quadruplet induction regimens
    Meeting Abstract

    Jurgens, E.; Firestone, R.; Maclachlan, K. H.; Nemirovsky, D.; Derkach, A.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U. A.; Rajeeve, S.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Evaluating tumor-intrinsic and patient-specific mechanisms of resistance to teclistamab in anti-BCMA exposed and naïve multiple myeloma
    Meeting Abstract

    Firestone, R.; McAvoy, D.; Shekarkhand, T.; Serrano, E.; Hamadeh, I. S.; Wang, A.; Zhu, M.; Patel, D.; Tan, C.; Hultcrantz, M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) vs daratumumab, carfilzomib, lenalidomide and dexamethasone (DKRd) as induction therapy in newly diagnosed multiple myeloma
    Meeting Abstract

    Tan, C. R.; Maclachlan, K.; Nemirovsky, D.; Derkach, A.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U.; Patel, D.; Shekarkhand, T.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Evolving M-spike and risk of progression in smoldering multiple myeloma
    Meeting Abstract

    Hultcrantz, M.; Nemirovsky, D.; Akhlaghi, T.; Maclachlan, K.; Korde, N.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Patel, D.; Shah, U.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Evaluating dynamic changes in the serum free light chain ratio and its effect on risk of progression in smoldering multiple myeloma
    Meeting Abstract

    Akhlaghi, T.; Nemirovsky, D.; Maclachlan, K.; Korde, N.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Patel, D.; Shah, U.; Tan, C. R.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save